U.S. Serial No. 10/525,410 Filed: January 26, 2005

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (original) A compound of the formula:

wherein A, B and D are independently chosen from either N or C, with the provision that at least one of A, B or D is N;

E is C or N;

R is H or C₁₋₄alkyl;

R² and R³ are independently H, C₁₋₃ alkyl, C₂₋₃ alkenyl, or R² and R³ taken together can form a 5 or 6 member ring;

X is hydrogen, halogen, C₁₋₄alkyl, or CF₃; and the dashed bond may be a single bond or a double bond; and pharmaceutically acceptable salts and solvates.

- 2. (original) The compound of claim 1, wherein the compound is 2-(8-bromo-benzo-[1,2-b;4,5-b']diffuran-4-yl) imidazoline hydrochloride.
- 3. (currently amended) A method for lowering intraocular pressure and providing neuroprotection comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a compound of the formula:

U.S. Serial No. 10/525,410 Filed: January 26, 2005

wherein A, B and D are independently chosen from either N or C, with the provision that at least one of A, B or D is N;

E is C or N;

R is H or C₁₋₄alkyl;

 R^2 and R^3 are independently H, C_{1-3} alkyl, C_{2-3} alkenyl, or R^2 and R^3 taken together can form a 5 or 6 member ring;

X is hydrogen, halogen, C₁₋₄alkyl, or CF₃; and the dashed bond may be a single bond or a double bond; and pharmaceutically acceptable salts and solvates.

- 4. (original) The method of claim 3, wherein the compound is 2-(8-bromo-benzo-[1,2-b;4,5-b"]difuran-4-yl) imidazoline hydrochloride.
- 5. (currently amended) A composition for lowering and controlling normal or elevated intraocular pressure and providing ocular neuroprotection, comprising a compound of the formula:

wherein A, B and D are independently chosen from either N or C, with the provision that at least one of A, B or D is N;

E is C or N;

R is H or C₁₋₄alkyl;

R² and R³ are independently H, C₁₋₃ alkyl, C₂₋₃ alkenyl, or R² and R³ taken together can form a 5 or 6 member ring;

X is hydrogen, halogen, C₁₋₄alkyl, or CF₃; and the dashed bond may be a single bond or a double bond; and pharmaceutically acceptable salts and solvates.

6. (original) The composition of claim 5, wherein the compound is 2-(8-bromo-benzo-[1,2-b;4,5-b"]diffuran-4-yl) imidazoline hydrochloride.

U.S. Serial No. 10/525,410 Filed: January 26, 2005

7. (original) The composition of claim 6, further comprising ophthalmologically acceptable

preservatives.

8. (original) The composition of claim 6, further comprising ophthalmologically acceptable

surfactants.

9. (original) The composition of claim 6, further comprising an agent to increase viscosity.

10. (original) The composition of claim 9, wherein the agent is selected from the group

consisting of hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose,

methylcellulose, and polyvinylpyrrolidone.

11. (original) The composition of claim 6, further comprising ophthalmologically acceptable

preservatives, ophthalmologically acceptable surfactants and at least one agent to increase

viscosity.

12. (original) The composition of claim 6, further defined as a topical ophthalmic suspension

or solution having a pH of about 5 to about 8.

13. (original) The composition of claim 12, wherein the concentration of the compound is from

.01% to 5% by weight.

14. (original) The composition of claim 13, wherein the composition of the compound is from

.25% to 2% by weight.

15. (canceled)

16. (canceled)

4